Allergan CEO Pyott steps down from Edwards' board; Philly jury sides with patient in Actos cancer case;

@FiercePharma: Top-read special report this weekend: Top 10 #pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Here's a profile on Pfizer's Susan Silbermann, whose #Vaccines unit has recently scored some big wins. More | Follow @CarlyHFierce

> Allergan ($AGN) CEO David Pyott stepped down from the Edwards Lifesciences ($EW) board, saying he needed to devote more time to his job as chairman and CEO of Allergan; Pyott has been fighting a hostile bid from Valeant Pharmaceuticals ($VRX). Report

> A Philadelphia jury awarded $2 million in compensation to a woman who claimed Takeda Pharmaceutical's diabetes drug Actos caused her bladder cancer. Report

> Merck ($MRK) said it would offer three series of euro-denominated notes; it plans to use the proceeds to buy back older debt. Release

> European regulators encouraged patients to report suspected side effects of the medications they use. Release

> Mylan ($MYL) rolled out its version of the HIV combination treatment Combivir, sold by ViiV Healthcare, in the U.S. Release

> GlaxoSmithKline ($GSK) appointed Credit Suisse Chairman Urs Rohner to its board of directors. Release

Medical Device News

@FierceMedDev: $BD to buy CareFusion for $12.2B to become more hospital-focused. Story | Follow @FierceMedDev

@VarunSaxena2: Medtronic undeterred by new regs, to finance acquisition of Covidien with external funds. More | Follow @VarunSaxena2

@EmilyWFierce: Pain-management outfit Nevro heads to market with plans for $125M IPO. Article | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." Report | Follow @MichaelGFierce

> Attorney questions FDA's authority to regulate devices promoted on social media. More

> BD to buy CareFusion for $12.2B to become more hospital-focused. Article

> Pain-management outfit Nevro heads to market with plans for $125M IPO. Story

Biotech News

@FierceBiotech: Check out our new feature: Top women in #biotech 2014. Special report | Follow @FierceBiotech

@JohnCFierce: Struggling $TEVA slashing R&D, chops 14 programs as it retreats on two fronts. More | Follow @JohnCFierce

@DamianFierce: $ZAFG's @TEHughes2009 on leaving Big Pharma for small biotech. Article | Follow @DamianFierce

@EmilyMFierce: Mining the microbiome for new therapeutics. Item | Follow @EmilyMFierce

> Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up. More

> Actavis snaps up Durata, newly approved antibiotic in $675M buyout. Article

> Sunesis shares crushed in a rout after leukemia PhIII ends in defeat. News

CRO News

> WuXi snags a stateside CRO to beef up its early-stage services. News

> Catalent bets on armed antibodies with Redwood buyout. Report

> Chiltern picks up an Asian CRO with eyes on oncology. Story

> Accelovance poaches a Big Pharma vet to lead its oncology efforts. Article

> European CRO Genae stretches out in the U.S. Item

Biotech IT News

> EMA overturns ban on data downloads in final transparency policy. News

> Facebook mulls move into healthcare sector. Item

> Wall Street turns to social-listening tools to guide pharma bets. Report

> Google joins BRAIN Initiative to help with petabyte-scale data sets. Article

> IT projects grab slice of $102M round of PCORI funding. More

Animal Health News

> Report: Integrated Animal Health to roll out pain patches for pets, other animals. Story

> FAO says control of Madagascar locust plague threatened by lack of funds. Item

> Neogen acquires BioLumix through purchase of outstanding stock. News

> Ceva spends $23M to upgrade its sterile products plant in France. Article

> Kansas State researchers get $1.1M NIH grant to study swine flu. More

And Finally... A patent settlement doesn't have to include cash to qualify as a pay-for-delay deal under the U.S. Supreme Court's Actavis ($ACT) decision, a judge said. Report (reg. req.)

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.